Congress on the Brink of Disrupting the PBM Market
During much of 2024, the prevailing view in Washington was that some policies related to pharmacy benefit managers (PBMs) would be included in the end-of-year continuing resolution.
Economics of “Delinking” Are Still Not Good
Delinking would lead to higher costs for patients and taxpayers and put more money in the pockets of brand drug manufacturers.
Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report
In July, MGA CEO Alex Brill submitted a comment letter to the Federal Trade Commission (FTC) expressing concerns about their newly released interim report.
The Economics of “Delinking” PBM Compensation
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
Unintended Consequences of Limiting PBMs
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
- Congress on the Brink of Disrupting the PBM Market
- Raising the Salt Cap Would Increase Tax Complexity
- Economics of “Delinking” Are Still Not Good
- The Child Tax Credit: Tradeoffs and Preferences
- Oregon’s Measure 118: The Turnover Tax Is the Worst
- Dueling Child Tax Credit Proposals: Harris vs. Vance
- Trump Proposes Bringing Back the Deduction for Auto Loan Interest
- Overtime Income Tax Break: Not Illogical, Just Costly and Complicated
- Presidential Candidates’ Dueling Child Credit Expansions Explained
- A Tip Exemption Is Not Sound Tax Policy
